Lansoprazol Aurovitas

Lansoprazole, the active ingredient in Lansoprazol Aurovitas, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, and peptic ulcer disease in adult patients.

GNH USA supplies Lansoprazol Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by lowering stomach acidity. - Erosive esophagitis: promotes healing of inflamed esophageal tissue caused by acid exposure. - Peptic ulcer disease: supports ulcer healing and prevents recurrence through acid suppression. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic gastric environment.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may improve with continued therapy. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of unease or urge to vomit. - Flatulence: increased intestinal gas. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing. - Clostridium difficile infection: severe diarrhea and colitis. - Low magnesium levels (hypomagnesemia): muscle cramps, seizures. - Elevated liver enzymes: potential liver injury. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder. - Interstitial nephritis: inflammation of kidney tissue.

Before initiating therapy with Lansoprazole, consider the following precautions. - Assess renal function: dose adjustment may be needed in severe impairment. - Use lowest effective dose: limit duration to the shortest period necessary. - Monitor long‑term use: watch for vitamin B12 deficiency and bone fracture risk. - Avoid in patients with known hypersensitivity to lansoprazole or other PPIs. - Consider elderly patients: increased susceptibility to adverse effects. - Store at room temperature: keep in the original container, protect from moisture.

Lansoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, compromising antiviral efficacy. - High‑dose methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer anticoagulation monitoring. - Diazepam: elevated plasma levels, may enhance sedation. - Digoxin: increased serum concentration, risk of toxicity.